Prostate cancer metastatic
Not recruitingStudy of enzalutamide alone versus enzalutamide with radium-223 combination in patients with bone metastatic castration-resistant prostate cancer with mild or no symptoms
Study of enzalutamide alone versus enzalutamide with radium-223 combination in patients with bone metastatic castration-resistant prostate cancer with mild or no symptoms
- Disease:Prostate cancer metastatic
- Substances:EnzalutamideRadium RA 223 dichloride
Ireland- Participants:18–64 years · 65+ years
- Substances:Enzalutamide
